PubRank

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)

Clinical Trial ID NCT01704287

PubWeight™ 26.77‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01704287

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015 4.04
2 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
3 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
4 Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 2018 1.38
5 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
6 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
7 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
8 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
9 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
10 Pembrolizumab. J Immunother Cancer 2015 0.99
11 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
12 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
13 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
14 Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013 0.94
15 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013 0.92
16 Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther 2015 0.88
17 Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014 0.88
18 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
19 Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 2016 0.84
20 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
21 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
22 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
23 Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs 2016 0.80
24 Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer 2016 0.77
25 Melanoma immunotherapy. Cancer Biol Ther 2014 0.76
26 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
Next 100